BR112023001595A2 - Fármacos antiplaquetários e usos dos mesmos - Google Patents

Fármacos antiplaquetários e usos dos mesmos

Info

Publication number
BR112023001595A2
BR112023001595A2 BR112023001595A BR112023001595A BR112023001595A2 BR 112023001595 A2 BR112023001595 A2 BR 112023001595A2 BR 112023001595 A BR112023001595 A BR 112023001595A BR 112023001595 A BR112023001595 A BR 112023001595A BR 112023001595 A2 BR112023001595 A2 BR 112023001595A2
Authority
BR
Brazil
Prior art keywords
compounds
antiplatelet drugs
pharmaceutical compositions
administering
methods
Prior art date
Application number
BR112023001595A
Other languages
English (en)
Portuguese (pt)
Inventor
Gu Zi-Qiang
Zhang Yuanchao
He Gongxin
Hou Kai
Wu Hao
Original Assignee
Shanghai Curegene Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Curegene Pharmaceutical Co Ltd filed Critical Shanghai Curegene Pharmaceutical Co Ltd
Publication of BR112023001595A2 publication Critical patent/BR112023001595A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR112023001595A 2020-07-29 2021-07-28 Fármacos antiplaquetários e usos dos mesmos BR112023001595A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020105513 2020-07-29
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof

Publications (1)

Publication Number Publication Date
BR112023001595A2 true BR112023001595A2 (pt) 2023-04-04

Family

ID=80037185

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001595A BR112023001595A2 (pt) 2020-07-29 2021-07-28 Fármacos antiplaquetários e usos dos mesmos

Country Status (14)

Country Link
US (2) US12410132B2 (https=)
EP (2) EP4188935A4 (https=)
JP (1) JP2023535815A (https=)
KR (2) KR102906376B1 (https=)
CN (4) CN119033782B (https=)
AR (1) AR123078A1 (https=)
AU (1) AU2021317436A1 (https=)
BR (1) BR112023001595A2 (https=)
CA (1) CA3186645A1 (https=)
ES (1) ES3046366T3 (https=)
IL (1) IL299979A (https=)
MX (1) MX2023001232A (https=)
TW (1) TW202214609A (https=)
WO (1) WO2022022559A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532A (zh) * 2023-06-29 2023-09-29 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) * 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) * 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
KR20150038369A (ko) * 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
NO2721243T3 (https=) * 2014-10-01 2018-10-20
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Also Published As

Publication number Publication date
EP4188935A4 (en) 2024-07-17
EP4342532B1 (en) 2025-09-03
KR20230047425A (ko) 2023-04-07
US20240279178A1 (en) 2024-08-22
MX2023001232A (es) 2023-05-15
EP4342532A2 (en) 2024-03-27
CN116194459A (zh) 2023-05-30
EP4342532C0 (en) 2025-09-03
AU2021317436A1 (en) 2023-02-23
CA3186645A1 (en) 2022-02-03
IL299979A (en) 2023-03-01
US12410132B2 (en) 2025-09-09
KR102906376B1 (ko) 2025-12-30
WO2022022559A1 (en) 2022-02-03
ES3046366T3 (en) 2025-12-01
CN117343000A (zh) 2024-01-05
EP4342532A3 (en) 2024-07-17
KR20250073569A (ko) 2025-05-27
JP2023535815A (ja) 2023-08-21
US20250333382A1 (en) 2025-10-30
CN119552111B (zh) 2026-01-02
TW202214609A (zh) 2022-04-16
CN119033782A (zh) 2024-11-29
CN119552111A (zh) 2025-03-04
EP4188935A1 (en) 2023-06-07
CN119033782B (zh) 2025-04-25
AR123078A1 (es) 2022-10-26

Similar Documents

Publication Publication Date Title
BR112023001595A2 (pt) Fármacos antiplaquetários e usos dos mesmos
BR112017003302A2 (pt) sal de adição de ácido do composto inibidor de trk
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112016022499A2 (pt) Produtos terapêuticos combinatórios supramoleculares
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015016796A8 (pt) modulador de receptor de androgênio, composição farmacêutica que os compreende e usos do mesmo
BR112013003682A2 (pt) métodos para tratar doenças neurodegenerativas
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
BR112021021557A2 (pt) Corpos de cetona confinados em microesferas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112014030325A2 (pt) composição farmacêutica para tratar ou prevenir doença neurodegenerativa e alimento funcional
BR112015019919A2 (pt) compostos bicíclicos
BR112022006394A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
BR112022002692A2 (pt) Agentes antimaláricos
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
MX2015012716A (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.
BR112017025189A2 (pt) composição e usos da mesma
CO2023000858A2 (es) Inhibidores de atr y usos de estos
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112022000944A2 (pt) Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]